MichaelThomasPulleyMDPhD
Neurology • Jacksonville, FLHeadache, Neurophysiology
Associate Professor, Neurology, University of Florida College of Medicine
Dr. Pulley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
580 W 8th St
UFJP Neurology
Jacksonville, FL 32209Phone+1 904-244-3960Fax+1 904-244-3425
Education & Training
Johns Hopkins UniversityFellowship, Clinical Neurophysiology, 1997 - 1998
Duke University HospitalResidency, Neurology, 1994 - 1997
Sinai Hospital of BaltimoreInternship, Internal Medicine, 1993 - 1994
University of Maryland School of MedicineClass of 1993
Certifications & Licensure
FL State Medical License 1998 - 2025
GA State Medical License 1998 - 2019
MD State Medical License 1998 - 1999
NC State Medical License 1994 - 1999- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Clinical Trials
- Efficacy of Methotrexate in Myasthenia Gravis Start of enrollment: 2009 Apr 01
- International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
- A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Start of enrollment: 2015 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 173 citationsSafety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric
The Lancet. Neurology. 2021-07-01 - 389 citationsSafety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01 - 127 citationsRituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.Michael K. Hehir, Lisa D. Hobson-Webb, Michael Benatar, Carolina Barnett, Nicholas Silvestri
Neurology. 2017-09-05
Press Mentions
Clinical Effects of the Self-Administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia GravisFebruary 17th, 2020
'Us Against ALS': Jacksonville Lawman, Family Make Every Minute Count; CEOs Join in Fundraiser for NonprofitJuly 19th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
